Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010987
Filing Date
2019-11-14
Accepted
2019-11-14 07:52:07
Documents
92
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q jagx-20190930x10q.htm 10-Q 3559448
2 EX-31.1 jagx-20190930ex311d2dd8a.htm EX-31.1 12639
3 EX-31.2 jagx-20190930ex312d93232.htm EX-31.2 12552
4 EX-32.1 jagx-20190930ex32186c7d2.htm EX-32.1 7932
5 EX-32.2 jagx-20190930ex322482cd1.htm EX-32.2 7859
  Complete submission text file 0001558370-19-010987.txt   13205294

Data Files

Seq Description Document Type Size
6 EX-101.INS jagx-20190930.xml EX-101.INS 2350393
7 EX-101.SCH jagx-20190930.xsd EX-101.SCH 113006
8 EX-101.CAL jagx-20190930_cal.xml EX-101.CAL 58130
9 EX-101.DEF jagx-20190930_def.xml EX-101.DEF 599572
10 EX-101.LAB jagx-20190930_lab.xml EX-101.LAB 808385
11 EX-101.PRE jagx-20190930_pre.xml EX-101.PRE 794753
Mailing Address 201 MISSION STREET, SUITE 2375 SAN FRANCISCO CA 94105
Business Address 201 MISSION STREET, SUITE 2375 SAN FRANCISCO CA 94105 415-896-5081
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36714 | Film No.: 191216373
SIC: 2834 Pharmaceutical Preparations